Analyst Ratings For iRadimed Corporation (NASDAQ:IRMD)
Today, iRadimed Corporation (NASDAQ:IRMD) stock received an upgrade by Roth Capital from Neutral to Buy.
There are 1 buy rating on the stock.
The current consensus rating on iRadimed Corporation (NASDAQ:IRMD) is Buy (Score: 3.00) with a consensus target price of $11.50 per share, a potential 17.35% upside.
Some recent analyst ratings include
- 7/31/2017-Roth Capital Upgrade from a “Neutral ” rating to a ” Buy” rating.
Recent Insider Trading Activity For iRadimed Corporation (NASDAQ:IRMD)
iRadimed Corporation (NASDAQ:IRMD) has insider ownership of 60.10% and institutional ownership of 17.26%.
- On 6/1/2017 Steven M Nardi, VP, sold 4,634 with an average share price of $8.32 per share and the total transaction amounting to $38,554.88. View SEC Filing
- On 2/9/2017 Roger E Susi, CEO, bought 10,000 with an average share price of $8.60 per share and the total transaction amounting to $86,000.00. View SEC Filing
- On 11/29/2016 Roger E Susi, CEO, bought 5,000 with an average share price of $11.24 per share and the total transaction amounting to $56,200.00. View SEC Filing
- On 11/15/2016 Roger E Susi, CEO, bought 5,000 with an average share price of $10.46 per share and the total transaction amounting to $52,300.00. View SEC Filing
- On 8/16/2016 Steven M Nardi, VP, sold 2,096 with an average share price of $17.11 per share and the total transaction amounting to $35,862.56. View SEC Filing
- On 6/14/2016 Monty K. Allen, Director, sold 2,275 with an average share price of $20.00 per share and the total transaction amounting to $45,500.00. View SEC Filing
- On 6/13/2016 Monty K Allen, Director, sold 2,100 with an average share price of $20.44 per share and the total transaction amounting to $42,924.00. View SEC Filing
Recent Trading Activity for iRadimed Corporation (NASDAQ:IRMD)
Shares of iRadimed Corporation closed the previous trading session at 9.80 0.00 0.00% with 89,983 shares trading hands.